Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01342770
Other study ID # NCI-2011-03826
Secondary ID NCI-2011-03826MA
Status Terminated
Phase Phase 2
First received April 23, 2011
Last updated October 30, 2017
Start date April 2011
Est. completion date February 2013

Study information

Verified date October 2017
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot phase II trial studies how well pioglitazone works in treating patients with stage IA-IIIA non-small cell lung cancer. Pioglitazone hydrochloride may slow the growth of tumor cells and may be an effective treatment for non-small cell lung cancer.


Description:

PRIMARY OBJECTIVES:

I. To evaluate the mechanism(s) of action of pioglitazone as a candidate chemopreventive agent for lung cancer by investigating the effects on Ki-67 defined in non-small cell lung cancer (NSCLC) tumor tissue.

SECONDARY OBJECTIVES:

I. To determine the effects of pioglitazone on multiple markers listed below:

- Tumor tissue: caspase-3, cyclin D1, p21/Waf1, peroxisome proliferative activated receptor, gamma (PPARγ), mucin 1 (MUC1).

- Premalignant tissue: Ki-67, caspase-3, PPARγ.

- Histologically normal tissue: Ki-67, PPARγ. II. To evaluate the toxicity and safety of pioglitazone in this patient population.

III. To analyze the expression of serum markers that are affected by pioglitazone.

IV. To describe the effects of limited treatment with pioglitazone on tumor metabolic activity as determined by FDG-PET (assessed before and after a minimum of 2 weeks of treatment).

OUTLINE:

Patients receive pioglitazone hydrochloride orally (PO) once daily (QD) for 14-42 days. Patients then undergo surgery.


Recruitment information / eligibility

Status Terminated
Enrollment 6
Est. completion date February 2013
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Suspected or biopsy-proven NSCLC

- Willingness to provide biopsy tissue for correlative studies

- Candidate for pulmonary resection; must be able to schedule >= 14 days and =< 42 days between registration and surgery to allow for treatment with pioglitazone

- Ability to understand and the willingness to sign a written informed consent document

- Ability and willingness to swallow oral tablets

- Ability and willingness to undergo two bronchoscopies (before treatment and at the time of surgery)

- For those participants who are undergoing mediastinoscopy as part of their standard-of-care, the pre-treatment bronchoscopy may be performed during the mediastinoscopy; if the participant remains eligible for definitive surgical resection after the mediastinoscopy, the participant may proceed to registration and pioglitazone treatment

- Current or former smoker with a >= 10 pack-year smoking history

- Women of child-bearing potential and men who agree to use adequate contraception for the duration of study participation; women must not be pregnant or lactating; women of child-bearing potential (women considered not of childbearing potential if they are at least two years postmenopausal and/or surgically sterile) must have used adequate contraception (abstinence; barrier methods such as intrauterine device [IUD], diaphragm with spermicidal gel, condom, or others; and hormonal methods such as birth control pills or others) since her last menses prior to study entry; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately

Exclusion Criteria:

- Receiving any other investigational agents

- History of allergic reactions attributed to compounds of similar chemical or biologic composition to pioglitazone

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

- Pregnant or lactating woman

- Currently treated diabetes

- Participants with >= class II New York Heart Association (NYHA) congestive heart failure or history of congestive heart failure

- Participants with >= grade 2 (moderate) edema

- Participants currently receiving an inhibitor of cytochrome P450 family 2, subfamily C, polypeptide 8 (CYP2C8) (gemfibrozil, ketoconazole, quercetin, trimethoprim), or an inducer of CYP2C8 (cortisol, dexamethasone, phenobarbital, rifampin), or cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) substrate

- Prior neoadjuvant therapy for NSCLC

- History of bladder cancer or in situ bladder cancer

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Laboratory Biomarker Analysis
Correlative studies
Drug:
Pioglitazone Hydrochloride
Given PO
Other:
Quality-of-Life Assessment
Ancillary studies

Locations

Country Name City State
United States Mayo Clinic Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent Change in Ki-67 by Immunohistochemistry (IHC) Changes in the expression levels of Ki-67 will be plotted graphically, and percent change in expression levels will be formally assessed using the paired t-test or the Wilcoxon signed rank test, if the assumptions of the t-test (i.e. normality) are not met. Baseline and at the time of surgery, after 42 days of treatment
Secondary Change in Apoptosis Assessment (e.g., Caspase-3) Changes in the expression levels (or grades) from baseline (prior to intervention) to post-intervention (resected tumor sample) will be plotted graphically as well as formally assessed using the McNemar's tests (for categorical variables) or Wilcoxon signed rank tests (for continuous variables) respectively. Baseline and at the time of surgery, after 42 days of treatment
Secondary Change in Levels of Serum CA-153 Each participant's pre- and post serum levels of CA-153 will be graphically represented and the mean levels analyzed using a paired t-test or Wilcoxon signed rank test, if the assumptions of the t-test are not met. Baseline and at the time of surgery, after 42 days of treatment
Secondary Change in Levels of Serum CRP Each participant's pre- and post serum levels of CRP will be graphically represented and the mean levels analyzed using a paired t-test or Wilcoxon signed rank test, if the assumptions of the t-test are not met. Baseline and at the time of surgery, after 42 days of treatment
Secondary Gene Expression Analysis of RNA From Bronchial Brush Cells For the gene expression profiles obtained from the data from normal bronchial brush cells, each participant's pre- and post gene expression will be graphically represented and the mean expression levels analyzed using a paired t-test or Wilcoxon signed rank test, if the assumptions of the t-test are not met. Up to the time of surgery, after 42 days of treatment
Secondary Incidence of Adverse Events Graded According to Common Terminology Criteria for Adverse Events Version 4.0 To evaluate the adverse events profile, the maximum grade for each type of adverse event will be recorded for each participant and frequency tables will be reviewed to determine the overall patterns. The number and severity of adverse events (both regardless of attribution as well as those that are at least possibly, probably, or definitely related) will be tabulated and summarized. Up to the time of surgery, after 42 days of treatment
Secondary Number of Participants With Clinical Response, Based on Response Evaluation Criteria in Solid Tumors ( RECIST) Version 1.1 Clinical response rates will be summarized. Complete response (CR) is the disappearance of all non-nodal target lesions (TL) and each target lymph node (LN) must have reduction in short axis to <1.0cm. Partial Response (PR) is at least a 30% decrease in the sum of the longest diameters (LD) of the non-nodal TR and the short axis of the target LN with the baseline sum diameters (BSD) as reference. Progression (PD) is at least 1 new malignant lesion or LN whose short axis increased to >1.5 cm or at least a 20% increase in the sum of TL diameters with the minimum sum of diameters as reference. Up to the time of surgery, after 42 days of treatment
Secondary Number of Participants With Complete Pathologic Response Complete pathologic response was defined as no viable residual tumor cells. Acellular residual mucin pools also considered a pathologic complete response. Up to the time of surgery, after 42 days of treatment
Secondary Percent Change in Cyclin D1 Changes in the expression levels from baseline (prior to intervention) to post intervention (resected tumor sample) will be plotted graphically. Baseline to the time of surgery, after 42 days of treatment
Secondary Percent Change in MUC1 Changes in the expression levels from baseline (prior to intervention) to post intervention (resected tumor sample) will be plotted graphically. Baseline to the time of surgery, after 42 days of treatment
Secondary Percent Change in p21 Changes in the expression levels from baseline (prior to intervention) to post intervention (resected tumor sample) will be plotted graphically. Baseline to the time of surgery, after 42 days of treatment
Secondary Percent Change in PPARy Changes in the expression levels from baseline (prior to intervention) to post intervention (resected tumor sample) will be plotted graphically. Baseline to the time of surgery, after 42 days of treatment
Secondary Percent Change in SUVmax From the PET Scan The percent change from pre to post-intervention in SUV max values will be summarized using descriptive statistics and simple graphical plots. Baseline to the time of surgery, after 42 days of treatment
Secondary Pre-intervention SUV of PET Scan The pre- and post-intervention SUV will be summarized using descriptive statistics and simple graphical plots. Baseline
Secondary Post-intervention SUV of PET Scan The pre- and post-intervention SUV will be summarized using descriptive statistics and simple graphical plots. Time of surgery, after 42 days of treatment
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01711697 - An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Phase 1
Completed NCT02364609 - Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib Phase 1
Terminated NCT02495896 - Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors Phase 1
Completed NCT01935336 - Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Phase 2
Withdrawn NCT01971489 - Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT00963807 - Trial Comparing the Use of FLT PET to Standard CT to Assess Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable NSCLC Phase 2
Completed NCT00093756 - Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer Phase 1/Phase 2
Completed NCT00049543 - Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Phase 3
Completed NCT02879994 - Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer Phase 2
Completed NCT02728596 - S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) N/A
Completed NCT02897375 - Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors Phase 1
Terminated NCT02566421 - Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery N/A
Withdrawn NCT02017925 - Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation N/A
Terminated NCT01707823 - Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer Early Phase 1
Terminated NCT01411098 - Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Phase 1
Completed NCT00778167 - Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT00738881 - Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer Phase 3
Completed NCT00074022 - GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors Phase 1/Phase 2
Terminated NCT01857271 - Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer Phase 2
Terminated NCT01413750 - Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer Phase 1/Phase 2